The president and chief executive officer of The ALS Association provided insight on how the organization is advancing the therapeutic pipeline of ALS agents for the foreseeable future. [WATCH TIME: 3 minutes]
Videos
The president and CEO of the Muscular Dystrophy Association spoke about the need for increased participation in neuromuscular disorder clinical trials and the rapid therapeutic progress the field is seeing. [WATCH TIME: 4 minutes]
The president and chief executive officer of The ALS Association expanded on the organization’s greatest goal—making ALS livable by 2030—and how it plans to work towards that over the next decade. [WATCH TIME: 3 minutes]
The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers and clinical professor of neurology at UCLA discussed the lack of a more focused and specific approach to care for women with Parkinson disease. [WATCH TIME: 6 minutes]
ACNS Critical Care EEG Terminology 2021 is a series dedicated to teaching an understanding of the American Clinical Neurophysiology Society's terminology. Check back for new episodes featuring special guests in the field.
The neurologist and assistant professor at the University of Toronto provided perspective on the multiple different ways retinal imaging can alter and improve the efficiency of research for Alzheimer disease. [WATCH TIME: 2 minutes]
The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending March 19, 2022.
An expert delves into the different types of immune responses a patient with MS can have to COVID-19 vaccines if they are also on DMTs.
Dr Schmierer explains how the SARS-CoV-2 infection and COVID-19 pandemic have impacted treating patients with MS with DMTs.
Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.
Expert panelists review the viability of new treatments in development for multiple sclerosis.
Alberto Ascherio, MD, DrPH, addresses the range of latency periods for Epstein-Barr virus and the impact on onset multiple sclerosis.
Alberto Ascherio, MD, DrPH; Anne Cross, MD; and Michael Racke, MD, discuss implications for patient communication and other advances from bench to bedside.
The expert panelists comment on intervention efforts underway to address multiple sclerosis prevention and treatment.
A panel of experts probe the variations in immune response to Epstein-Barr virus in patients with multiple sclerosis.
Alberto Ascherio, MD, DrPH, highlights key risk factors leading to increased prevalence of multiple sclerosis.
Anne Cross, MD, and Michael Racke, MD, discuss how the immune system is primed in multiple sclerosis.
Avindra Nath, MD, explains the importance of understanding virology when treating autoimmune diseases.
Alberto Ascherio, MD, DrPH, recaps key findings and learning from a recently published study that he coauthored demonstrating a causal relationship between MS and Epstein-Barr virus.
The neurologist and assistant professor at the University of Toronto commented on the next research efforts needed to further validate and demonstrate the diagnostic capabilities of RetiSpec. [WATCH TIME: 3 minutes]
The chairman of the department of neurology at George Washington University discussed the reasons to be optimistic, but cautiously, about the expanding myasthenia gravis treatment toolbox. [WATCH TIME: 3 minutes]
The president and CEO of the Muscular Dystrophy Association spoke about the highlights of this year’s annual meeting and the recent therapeutic advances for neuromuscular disorders. [WATCH TIME: 3 minutes]
The chairman of the department of neurology at George Washington University discussed his presentation at MDA 2022 and the value of hearing patient perspective at the conference. [WATCH TIME: 2 minutes]
The director of neuromuscular clinical trials at Columbia University Irving Medical Center shared her perspective on the challenges of familiarizing oneself with the influx of novel medications for neuromuscular diseases. [WATCH TIME: 3 minutes]
The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University offered his insight into the advances in genetic approaches to LGMD. [WATCH TIME: 2 minutes]
The 2022 MDA National Ambassador and patient with Bethlem myopathy spoke to the critical need to improve diagnosis delays in neuromuscular disorders and effective communication between patients and their physicians. [WATCH TIME: 2 minutes]
The founding chair of the department of brain health at the University of Nevada Las Vegas discussed the plethora of Alzheimer disease biomarkers and the need for consensus on the value of each. [WATCH TIME: 3 minutes]
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
The 2022 MDA National Ambassador and patient with Bethlem myopathy spoke to the importance of including the patient perspective at medical meetings to improve the care paradigm in neuromuscular disorders. [WATCH TIME: 3 minutes]
Advertisement
Advertisement
